Avidity Biosciences to Participate in Upcoming Investor Conference

Rhea-AI Summary

Avidity Biosciences (Nasdaq: RNA), a developer of Antibody Oligonucleotide Conjugates (AOCs™), has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference. The company's management will engage in a fireside chat scheduled for Tuesday, April 8, 2025, at 3:00 p.m. ET.

Investors and interested parties can access the live webcast and replay of the presentation through the 'Events and Presentations' section on Avidity's investor relations website at aviditybiosciences.investorroom.com/events-and-presentations.

News Market Reaction

-9.42%

1 alert

-9.42% News Effect

On the day this news was published, RNA declined 9.42%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN DIEGO, April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference:

• 24^th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET

Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.

About Avidity

Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X.

Investor Contact:
Kat Lange
(619) 837-5014
investors@aviditybio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conference-302416463.html

SOURCE Avidity Biosciences, Inc.

FAQ

When is Avidity Biosciences (RNA) presenting at the Needham Healthcare Conference 2025?

Avidity Biosciences will present on Tuesday, April 8, 2025, at 3:00 p.m. ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors watch Avidity Biosciences' (RNA) Needham Conference presentation?

Investors can watch the live webcast and replay through Avidity's website at aviditybiosciences.investorroom.com/events-and-presentations.

What type of presentation will Avidity Biosciences (RNA) give at the Needham Conference?

Avidity Biosciences management will participate in a fireside chat format presentation.

What is Avidity Biosciences' (RNA) main therapeutic focus?

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs™), a new class of RNA therapeutics.